PhRMA takes aim at Thailand for production of generics, hints that it will push for sanctions

Swanson, Ian
May 2007
Hill;5/23/2007, Vol. 14 Issue 62, p24
The article reports on the move initiated by drug companies in the U.S. to force Thailand and other developing countries to recognize U.S. drug patents. The Pharmaceutical Research and Manufacturers Association in the U.S. was struck by the decision of Thailand to produce the generic version of two AIDS drugs which are still under the patent of a U.S. drug firm. A representative from the U.S. negotiate with officials from Thailand to help solve the intellectual property issue of the medicine.


Related Articles

  • Intellectual Property Regime.  // Canada Pharma & Healthcare Report;Q3 2011, Issue 3, p18 

    The article discusses the intellectual property development in the Canadian pharmaceutical sector. The "Romanow Report" states that the main issues of patent rights of drugs and medical devices are evergreening habits and notice of compliance rules. The drug market in the Canadian province of...

  • Compulsory licensing -- To what extent is it practicable? Janodia, Manthan D.; Rao, J. Venkata; Udupa, N. // Current Science (00113891);10/25/2006, Vol. 91 Issue 8, p998 

    The article focuses on compulsory licensing in the pharmaceutical industry in India. Compulsory licensing is an aspect of the Trade-Related Aspects of Intellectual Property Rights agreement that allows countries to use flexibility accorded under the agreement. This aspect affects the...

  • Pushing Patents. Babyak, Richard // Appliance Design;Jun2005, Vol. 53 Issue 6, p5 

    Comments on issues concerning the patenting of commercial products. Flaw in the patenting system in Australia; Disadvantage of incomplete electronic databases to the task of patent examiners; Criticisms against the U.S. patent office.

  • No Exception? Buck, Margaret // Pharmaceutical Executive;May2005, Vol. 25 Issue 5, p66 

    The article focuses on a legal loophole that has made patented tools available for research. Although biotechnology research has exploded in the past three decades, a parallel explosion seems, at first glance, to threaten those scientific achievements. Patents provide incentive for biomedical...

  • TRIALS AND TRIPS-ULATIONS: INDIAN PATENT LAW AND NOVARTIS AG V. UNION OF INDIA. Lee, Linda L. // Berkeley Technology Law Journal;2008 Annual Review, Vol. 23 Issue 1, p281 

    The article focuses on the emerging debate regarding intellectual property rights in India. Novartis AG v. Union of India has grabbed the attention of multinational pharmaceuticals concerned about the generic market and the international community concerned about India's compliance with the...

  • Whose Property Is It, Anyway?  // European Pharmaceutical Executive;May/Jun2006, p18 

    The article discusses the need for the pharmaceutical industry to change its attitude towards intellectual property to survive the changing climate of patent rights in Europe. It focuses on the issue of whether the possession of a single patent was sufficient grounds to bring someone else's...

  • Domestic Patents - Questions You Should Ask Your Patent Attorney. Pershes, Robert; Wagner, Louis // BioPharm International;Aug2005, Vol. 18 Issue 8, p10 

    Explores the steps in seeking and managing a patent for pharmaceutical products in the U.S. Assessment on the suitability of a drug discovery to be patented; Consideration of the free use provisions of the teachings and protection contained in the patent; Factor posing literal infringement of...

  • Beware of the troll. Macdonald, Morag // Lawyer;9/26/2005, Vol. 19 Issue 37, p26 

    Explains why Europe needs to be prepared with patent troll, a phenomenon in which a company licenses out the patents and enforces them against those who refuse to take a license. Prevalence of the phenomenon in the United States; Reasons why Europe is less attractive to the business model of...

  • BIG PHARMA FIGHTS FOR IP. Walters, Kath // BRW;10/8/2009, Vol. 31 Issue 40, p57 

    The article reports on the litigation for intellectual property (IP) in the pharmaceutical industry. It notes that IP is one of the areas of practice that supported pharmaceutical companies during the global financial crisis. It mentions that the patents of hundreds of drugs are nearing its end...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics